Obtenir l’app Télécharger dans l’App Store

Recherche Peptidia

Les données probantes sont le produit.

Des aperçus sans données posologiques, des guides pour comprendre la recherche et des comparaisons transparentes de produits. Chaque page nomme ses limites, lie ses sources et porte une véritable date de révision éditoriale.

Aperçus révisés des données probantes

Commencez par ce que les données probantes les plus solides ont réellement montré.

Seuls les dossiers approuvés par l’équipe éditoriale sont publics. Il s’agit d’aperçus concis, pas de la bibliothèque complète réservée aux abonnés.

Aperçu du Passeport des données probantes

BPC-157

BPC-157 is a synthetic 15-amino-acid peptide. It is not approved as a medicine by the FDA or Health Canada, and WADA prohibits it at all times. Almost all evidence comes from rat studies, much of it from one research group in Zagreb. A 2026 systematic review found only three small uncontrolled human studies, 30 people in total, with very low certainty. A placebo-controlled trial in hamstring strain is registered and recruiting but has no results yet.

9 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

TB-500

TB-500 is a short fragment of thymosin beta-4 that FDA identifies by the sequence LKKTETQ. It is not approved for any use by the FDA or Health Canada, and WADA prohibits it at all times. FDA says it has found no human exposure data for products containing the fragment. The small human trials often cited tested full-length thymosin beta-4 for dry eye and skin ulcers, not TB-500, and not muscle or tendon repair.

8 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

GHK-Cu

GHK-Cu is a naturally occurring three-amino-acid peptide (glycyl-histidyl-lysine) bound to copper and an established cosmetic skin ingredient. It is not approved by the FDA or Health Canada for any therapeutic or injectable use. Topical claims rest mostly on cell and animal studies plus small cosmetic studies, several with commercial ties. Injected use has no human efficacy or safety data, and FDA flags safety risks for injectable compounded products.

7 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

KPV

KPV is a three-amino-acid peptide (lysine-proline-valine), the final segment of alpha-melanocyte-stimulating hormone. It is not approved as a medicine by the FDA or Health Canada. All cited evidence comes from cell and mouse studies of intestinal inflammation. No human trial is among the sources, and FDA says it has found no human exposure data for products containing KPV by any route.

7 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

Thymosin Alpha-1

Thymosin alpha-1 is an immune-signaling peptide first isolated from thymus tissue. It is not approved by the FDA or Health Canada. It has been tested in randomized human trials: a large phase 3 sepsis trial found no clear reduction in 28-day mortality, and a 2026 Cochrane review of chronic hepatitis B trials rated the evidence low to very low certainty. Benefits for general wellness have not been studied in these trials.

8 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

Retatrutide

Retatrutide is an investigational drug that acts on three receptors: GLP-1, GIP and glucagon. It is not approved by the FDA or Health Canada. Two phase 3 randomized trials published in 2026, both funded by Eli Lilly, found more weight loss than placebo over 80 weeks in adults with obesity, with or without type 2 diabetes. Gastrointestinal effects were the most common adverse events. Long-term safety and outcome benefits are not established.

9 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

Semaglutide

Semaglutide is a GLP-1 receptor agonist approved by the FDA and authorized by Health Canada. In the United States it is sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management, with label indications that also cover cardiovascular risk reduction, kidney outcomes in diabetes and a liver condition. Large randomized trials support these uses. The labels carry a boxed warning about thyroid C-cell tumors seen in rodents.

12 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA and authorized by Health Canada. In the United States it is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea with obesity. Randomized trials, including direct comparisons with semaglutide, support these uses. Benefits depend on continued treatment, and the labels carry a boxed warning about thyroid C-cell tumors seen in rats.

10 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

MOTS-c

MOTS-c is a small peptide encoded in mitochondrial DNA. It is not approved by the FDA or Health Canada for any use. In mice, giving MOTS-c prevented diet-induced and age-related insulin resistance, prevented diet-induced obesity and improved physical capacity. In humans, the evidence is observational: exercise raises the body's own MOTS-c levels. No published controlled trial among the reviewed sources has tested MOTS-c as a treatment in people, so its human effects and safety are unknown.

7 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

NAD+

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell. It is not a peptide, and the FDA has not approved it as a drug. Human trials of oral precursors such as nicotinamide riboside show that they raise NAD levels in the blood and are well tolerated in the short term. Clinically meaningful benefits for energy, aging or disease are largely unproven, and the reviewed trials did not test infused or injected NAD+.

6 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

AOD-9604

AOD-9604 is a synthetic fragment based on the end region of human growth hormone. Animal studies supported a fat-metabolism hypothesis, but the human development program did not establish meaningful weight-loss efficacy and was discontinued. It is not approved as a treatment for obesity or another clinical condition.

12 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

CJC-1295 (with DAC)

CJC-1295 with DAC is a synthetic, long-acting analog of growth hormone-releasing hormone. No FDA- or Health Canada-approved product exists. Small studies in healthy adults, from one development program, showed prolonged rises in growth hormone and IGF-1. No trial has tested recovery, muscle, or long-term health outcomes. FDA reports that the developer withdrew it from clinical trials in 2006 after a participant in an unpublished phase 2 trial died; the attending physician thought undiagnosed heart disease the most likely cause.

8 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

Sermorelin

Sermorelin is a synthetic copy of the first 29 amino acids of human growth hormone-releasing hormone. FDA approved it as Geref in 1990; Geref is discontinued, and FDA records that it was not withdrawn for safety or effectiveness reasons. No current FDA- or Health Canada-approved product was found. Its evidence is thin: older receptor and diagnostic studies, but no modern randomized trial of recovery, muscle, sleep, or aging outcomes.

10 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone. FDA approved it, sold as Egrifta, for the reduction of excess abdominal fat in adults with HIV and lipodystrophy. Phase 3 trials in that population showed less visceral fat than placebo, with little change in body weight. Its label says it is not indicated for weight loss, and benefit outside HIV is not established.

6 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

MK-677 (Ibutamoren)

MK-677, also called ibutamoren, is not a peptide. It is an orally active small molecule that activates the ghrelin receptor and raises growth hormone and IGF-1. It is not approved by FDA or Health Canada, and FDA excludes it from the dietary supplement definition. A randomized trial found no effect on Alzheimer disease progression, and a hip-fracture trial ended early over a congestive heart failure safety signal.

10 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

IGF-1 LR3

IGF-1 LR3 is a synthetic, modified form of insulin-like growth factor 1 that binds poorly to the proteins that normally carry IGF-1 in the blood. It is not approved as a therapeutic by FDA or Health Canada, and WADA prohibits it. The cited evidence is animal studies and an anti-doping detection method. No human trial has tested its efficacy or safety.

6 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

Ipamorelin

Ipamorelin is a synthetic peptide that activates the ghrelin receptor and stimulates endogenous growth-hormone release. It has never been approved by FDA or Health Canada. Its selectivity is documented mainly in preclinical studies. The strongest controlled human trial, in postoperative ileus, did not show a significant benefit on its key or secondary efficacy outcomes, and marketed wellness claims remain unproven.

9 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

Epitalon

Epitalon is a synthetic four-amino-acid peptide that is not approved by the U.S. Food and Drug Administration or Health Canada. Its telomere effects are cell-culture and rodent findings. The human studies are small, mostly open-label, and concentrated in one St. Petersburg research group. The popular claim that it lowers mortality comes from a study of Epithalamin, a pineal extract, not of Epitalon. There is no randomized, blinded efficacy trial and no human lifespan trial.

7 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

Semax

Semax is a synthetic heptapeptide based on a fragment of the hormone ACTH. It is not approved by the U.S. Food and Drug Administration or Health Canada. Most of its evidence comes from rodent studies of brain growth factors and neurochemistry. The one human study here followed patients recovering from ischemic stroke and did not describe randomization or blinding. No study in this entry tested cognition in healthy people.

10 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

SS-31 (Elamipretide)

SS-31, or elamipretide, is a mitochondria-targeted peptide approved by the U.S. Food and Drug Administration, under accelerated approval, as FORZINITY to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kilograms. Continued approval may depend on a confirmatory trial. A Phase III trial in primary mitochondrial myopathy missed its primary outcomes. No trial shows that it slows aging or raises energy in healthy people, and Health Canada has not authorized it.

9 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

PT-141

PT-141, or bremelanotide, is a melanocortin receptor agonist approved by the U.S. Food and Drug Administration as VYLEESI for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Two Phase 3 trials showed modest but statistically significant gains in desire and less distress. It is not approved for men or postmenopausal women, or to enhance sexual performance, and Health Canada has not authorized it.

8 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

Melanotan II

Melanotan II is a synthetic, nonselective melanocortin receptor agonist that is not approved by the U.S. Food and Drug Administration or Health Canada. Small, older controlled studies in men reported erections and increased sexual desire, with nausea and yawning as frequent side effects. Case reports describe new or changing moles and melanomas during or after use. It is a different compound from the approved drugs afamelanotide and bremelanotide.

10 sources consultables · Révisé en août 2026

Aperçu du Passeport des données probantes

Selank

Selank is a synthetic peptide derived from tuftsin and developed in Russia. Limited human studies report anxiety-related and neuroimaging signals, but the evidence base is small and geographically concentrated; most proposed mechanisms are preclinical. It is not approved by the U.S. Food and Drug Administration or Health Canada.

8 sources consultables · Révisé en août 2026

Comprendre la recherche

Un meilleur filtre pour la prochaine affirmation que vous rencontrerez.

Guide

Comment évaluer la recherche sur les peptides sans se perdre dans le battage médiatique

Une méthode reproductible pour vérifier les affirmations sur les peptides : déterminer le type de données probantes, la population, le résultat, le comparateur, les limites et le contexte réglementaire.

8 min · 4 sources

Guide

Ce que signifient les données probantes précliniques, et ce qu’elles ne permettent pas de conclure

Un guide en langage clair sur la recherche cellulaire, animale et mécanistique concernant les peptides, l’écart de transposition et les questions à poser avant d’extrapoler les résultats à l’humain.

7 min · 4 sources

Guide

Citations vs evidence quality: why a long reference list is not enough

Learn how to move from citation count to study design, directness, bias, precision, consistency, and applicability.

7 min · 3 sources

Guide

How to read a ClinicalTrials.gov record without overclaiming

A field-by-field guide to study status, sponsor, design, outcomes, enrollment, posted results, and record history.

8 min · 3 sources

Guide

Randomized controlled trials explained for peptide research

Understand randomization, control groups, blinding, prespecified outcomes, attrition, and why trial design still needs interpretation.

8 min · 3 sources

Guide

Systematic reviews explained: what makes a synthesis trustworthy?

Learn how a systematic review differs from a narrative overview and how to inspect its question, search, selection, bias assessment, synthesis, and certainty.

8 min · 4 sources

Guide

Biomarkers vs clinical outcomes: what did the study actually change?

Understand the difference between a biological measurement, a surrogate endpoint, and an outcome that directly reflects how people feel, function, or survive.

7 min · 3 sources

Guide

Statistical significance vs practical importance in research

Learn why a threshold-based result does not reveal effect size, precision, clinical relevance, bias, or the full evidence context.

7 min · 3 sources

Guide

Sample size and study power: why small studies mislead

Understand precision, events, variability, statistical power, and why a small positive or negative study rarely settles a peptide claim.

7 min · 3 sources

Guide

Conflicts of interest in peptide research: how to read them

A practical method for examining funding, author relationships, sponsor control, analysis, reporting, and replication without dismissing evidence by association.

8 min · 3 sources

Guide

Regulatory approval vs evidence: four distinctions that matter

Understand the difference between being studied, authorized for research, approved for a specific use, compounded, and promoted online.

8 min · 3 sources

Guide

Compounded peptides and evidence: product quality is a separate question

Learn why published molecule research, regulatory approval, compounding standards, and the identity of a specific preparation must be evaluated separately.

8 min · 3 sources

Guide

WADA and peptide research in 2026: what athletes need to verify

A research-focused guide to the World Anti-Doping Agency prohibited list, jurisdiction, in-competition rules, and current verification.

7 min · 3 sources

Guide

Peptidia’s Source Strength Score: what it says and what it cannot say

A transparent explanation of evidence tiers, directness, study quality, consistency, and why no single score can replace reading the sources.

7 min · 3 sources

Guide

Why negative trials matter in peptide research

Learn how a well-designed negative study updates an evidence record, why absence of significance is not always proof of no effect, and why unfavorable findings are easy to miss.

7 min · 3 sources

Guide

Research freshness and review dates: when an evidence page goes stale

A practical standard for search cutoffs, editorial review dates, regulatory checks, corrections, retractions, and rapidly changing evidence.

7 min · 4 sources

Guide

The Peptidia Evidence Passport: a field guide

Understand the evidence-maturity label, source strength, uncertainty, negative findings, review date, and boundaries shown on Peptidia profiles.

7 min · 4 sources

Choix de produits

Des comparaisons qui rendent le conflit visible.

Peptidia n’est pas un observateur neutre dans les pages qui la comparent. Nous l’indiquons clairement, nous datons chaque examen de produit et nous lions les fiches officielles qui étayent chaque affirmation.

Comparaison

Meilleures applications de recherche sur les peptides en 2026 : choisissez selon votre besoin

Une comparaison transparente des applications de recherche sur les peptides pour examiner les données probantes, consulter une référence générale et faire un suivi privé, selon les fiches officielles actuelles des produits.

7 min · Méthodologie divulguée

Comparaison

Peptidia ou PepPedia en 2026 : interface de données probantes ou boîte à outils tout-en-un?

Une comparaison de Peptidia et de PepPedia axée sur les données probantes, y compris le public de chaque application, les éléments mis de l’avant dans leurs fiches publiques et les compromis.

6 min · Méthodologie divulguée

Solutions de rechange

Solutions de rechange à PepPedia en 2026 : trois façons différentes d’étudier les peptides

Des solutions de rechange à PepPedia pour examiner les données probantes, faire un suivi personnel ou consulter directement les sources avec PubMed et ClinicalTrials.gov.

6 min · Méthodologie divulguée

Comparaison

Peptidia vs PeptidePal in 2026: which peptide tracker fits your job?

A transparent comparison of Peptidia and PeptidePal based on their official App Store listings: personal records, planning tools, privacy, and evidence.

6 min · Méthodologie divulguée

Comparaison

PepPedia vs PeptidePal in 2026: broad reference or tracker-first app?

A source-linked comparison of PepPedia and PeptidePal, with Peptidia included as a third option that pairs a private Lab with cited evidence.

6 min · Méthodologie divulguée

Comparaison

Peptidia vs PubMed in 2026: evidence summary or literature database?

Understand when to use Peptidia’s editorial summaries and when to search PubMed’s biomedical literature database directly.

6 min · Méthodologie divulguée

Comparaison

Peptidia vs ClinicalTrials.gov in 2026: editorial context or trial record?

A practical guide to using Peptidia alongside ClinicalTrials.gov without confusing a registered study with a completed positive result.

6 min · Méthodologie divulguée

Solutions de rechange

PeptidePal alternatives in 2026: five options for different jobs

Compare PeptidePal alternatives for evidence research, broad reference, journaling, and tracking using official product listings.

8 min · Méthodologie divulguée

Comparaison

Best peptide tracking apps in 2026: compare the tracking job first

A transparent 2026 comparison of peptide tracking apps, including Peptidia’s private Lab, based on each app’s official App Store listing.

8 min · Méthodologie divulguée

Comparaison

Best peptide journal apps in 2026: private records without evidence confusion

Compare peptide journal and tracking apps by privacy, export, research context, and the difference between observations and evidence.

7 min · Méthodologie divulguée

Comparaison

Best peptide research tools in 2026: a complete evidence workflow

Build a peptide research workflow with Peptidia, PubMed, ClinicalTrials.gov, FDA resources, and systematic-review guidance.

8 min · Méthodologie divulguée

Solutions de rechange

Peptide tracker alternatives in 2026: research, journals, or simple records?

Alternatives to your current peptide tracker: a private Lab with cited evidence, a combined reference and journal, another tracker, or a minimal private record.

7 min · Méthodologie divulguée

Solutions de rechange

Peptide calculator alternatives in 2026: when research is the real need

A safety-first look at alternatives to peptide calculator apps, including evidence resources and qualified clinical support.

7 min · Méthodologie divulguée

Expérience iPhone complète

Sources, incertitude et dates de révision — où que vous fassiez vos recherches.

L’app Peptidia ajoute la bibliothèque révisée complète, des fiches d’études consultables, des questions étayées et un Labo privé pour vos propres données.

Télécharger dans l’App Store

Renseignements éducatifs seulement. Ne constitue pas un avis médical. Aucune recommandation personnalisée ni donnée posologique numérique n’est fournie. Peptidia ne vend pas de peptides et ne recommande aucun fournisseur.